Hôpital Cochin

Paris 15 trials 8 recruiting

15 Registered trials

8 Currently recruiting

Organisation

Hôpital Cochin

Location

Paris, France

Identifier

ORL-000001229

Address

27 rue du Fbg St Jacques, 75014, France

Departments

Cardiology
CIC 1417 Cochin Pasteur
gastro enterology
Haematology
Internal Medicine
Medical oncology department
ONCOLOGIE
ONCOLOGIE MEDICALE
PneumologY
Service d'Hematologie
Service de chirurgie ophtalmologique
Service de Pneumologie

Clinical trials at this site (15)

Search interface

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) Recruiting

2024-512358-78-00 Solid Tumors 7 2015-01-20
UrsoDeoxyCholic Acid (UDCA) as neuroprotective treatment adjuvant to rhegmatogenous retinal detachment surgery Recruiting

2023-505106-41-01 rhegmatogenous retinal detachment 5 2024-08-20
SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate… Recruiting

2024-511309-47-00 moderate thrombocytopenia 4 2024-07-17
FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and … Recruiting

2023-506590-35-00 Large-Cell NeuroEndocrine Carcinoma of the lung 4 2024-06-13
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Relapsed/Refractory Multiple Myeloma 5 2024-05-27
Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study Recruiting

2023-503481-23-00 Maintenance treatment in metastatic non-squamous lung c 5 2023-03-20
Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small… Recruiting

2023-505924-71-00 Adult patients with metastatic and/or unresectable Non- 4 2021-05-12
A phase 1/2a multicenter trial to evaluate the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster in adu… Ended

2024-516767-92-01 Health Participants 1 2025-06-17
PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first… Ended

2024-518553-41-00 colon cancer and rectal with liver metastasis 5 2024-11-08
Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc… Ended

2023-510097-14-00 Patients with MMR deficient relapse or advanced / metas 5 2022-04-15
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended

2023-504959-27-00 Participants with Limited Stage-Small Cell Lung Cancer, 5 2020-12-09
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Ended

2024-513455-33-00 Bone sarcoma 4 2014-09-11
Efficacy of tocilizumab in the treatment of acute anterior ischemic optic neuropathy optic neuropathy in Horton's disease Ended

2024-519977-20-00 Acute Anterior Ischemic Optic Neuropathy associated wit 4 2025-01-27
Investigation to assess the effects of zalunfiban in patients with an acute heart attack Ended

2023-508485-15-00 Subjects with documented STEMI, presenting with persist 5 2021-04-22